NYSEAMERICAN:BPMX

Biopharmx (BPMX) Stock Forecast, Price & News

$0.26

0.00 (0.00%)

(As of 05/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.25
▼
$0.26
50-Day Range: N/A
52-Week Range: $0.25
▼
$6.30

Volume: 264,128 shs
Average Volume: 2.15 million shs
Market Capitalization: $4.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter.

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

March 31, 2022 | globenewswire.com

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results - GlobeNewswire

March 16, 2022 | finance.yahoo.com

Acne Drugs Global Market Report 2022 - Yahoo Finance

December 23, 2021 | benzinga.com

2021 Metabolic Partnering Global Report - In-depth Understanding of Metabolic Deal Trends Since 2014 - Be - Benzinga

December 15, 2021 | globenewswire.com

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology - GlobeNewswire

November 16, 2021 | streetinsider.com

Form 10-Q Timber Pharmaceuticals, For: Sep 30 - StreetInsider.com

October 13, 2021 | streetinsider.com

Venus Concept Appoints Ross J. Portaro as President of Global Sales - StreetInsider.com

October 13, 2021 | streetinsider.com

Form 8-K Venus Concept Inc. For: Oct 05 - StreetInsider.com

October 11, 2021 | globenewswire.com

Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis - GlobeNewswire

August 31, 2021 | streetinsider.com

Form PRER14A NEXTGEN HEALTHCARE, INC. - StreetInsider.com

August 23, 2021 | streetinsider.com

Form PRE 14A NEXTGEN HEALTHCARE, INC. For: Oct 13 - StreetInsider.com

August 10, 2021 | globenewswire.com

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results - GlobeNewswire

July 22, 2021 | streetinsider.com

Gelteq Appoints Seasoned Pharma and Tech Executive, James Pekarsky, as Chief Financial Officer - StreetInsider.com

May 12, 2021 | ca.finance.yahoo.com

Prothena: Q1 Earnings Snapshot - Yahoo Canada Finance

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:BPMX
Previous Symbol: NYSE:BPMX
CUSIP: N/A
CIK: N/A
Web: www.biopharmx.com
Phone: +1-650-8895020
Fax: N/A
Employees: 17
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 18,278,000
Free Float: N/A
Market Cap: $4.66 million
Optionable: Not Optionable

Company Calendar

Last Earnings: 12/10/2019
Today: 5/17/2022

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biopharmx.

5.0 Community Rank

Outperform Votes
Biopharmx has received 308 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biopharmx has received 96 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biopharmx has received 76.24% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote “Outperform” if you believe BPMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biopharmx does not currently pay a dividend.
Dividend Growth
Biopharmx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biopharmx insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

How were Biopharmx's earnings last quarter?: Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.96.
View Biopharmx's earnings history.
When did Biopharmx's stock split? How did Biopharmx's stock split work?: Biopharmx's stock reverse split on the morning of Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split.
Who are Biopharmx's key executives?: Biopharmx's management team includes the following people:
Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
Dr. José Zayas, Sr. VP of Operations
Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs
Who are some of Biopharmx's key competitors?: Some companies that are related to Biopharmx include IXICO (IXI), Oxford BioDynamics (OBD), NetScientific (NSCI), ValiRx (VAL), ImmuPharma (IMM), Bioasis Technologies (BTI), Fusion Antibodies (FAB), Quest PharmaTech (QPT), Crescita Therapeutics (CTX), Hvivo (HVO), Hemogenyx Pharmaceuticals (HEMO), Realm Therapeutics (RLM), Sigyn Therapeutics (SIGY), IBEX Technologies (IBT) and Medicure (MPH).
View all of BPMX's competitors.
What other stocks do shareholders of Biopharmx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).
What is Biopharmx's stock symbol?: Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How do I buy shares of Biopharmx?: Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biopharmx's stock price today?: One share of BPMX stock can currently be purchased for approximately $0.26.
How much money does Biopharmx make?: Biopharmx has a market capitalization of $4.66 million.
How many employees does Biopharmx have?: Biopharmx employs 17 workers across the globe.
What is Biopharmx's official website?: The official website for Biopharmx is www.biopharmx.com.
How can I contact Biopharmx?: Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.